Mutational Profiling of Pediatric Myeloid Leukemia Subtypes without Clinically Significant Chromosomal Aberrations
- Authors: Ghukasyan L.G.1, Krasnov G.S.1, Muravenko O.V.1, Baidun L.V.2, Ibragimova S.Z.3, Nasedkina T.V.1,4
-
Affiliations:
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Russian Children’s Clinical Hospital, Pirogov Russian National Research Medical University
- Scientific Research Institute of Haematology and Blood Transfusion
- Dmitry Rogachev National Medical and Research Center of Pediatric Haematology, Oncology and Immunology
- Issue: Vol 53, No 3 (2019)
- Pages: 354-361
- Section: Genomics. Transcriptomics
- URL: https://journal-vniispk.ru/0026-8933/article/view/163928
- DOI: https://doi.org/10.1134/S0026893319030087
- ID: 163928
Cite item
Abstract
The discovery of novel significant molecular and genetic markers is important for the diagnostics, prognosis, and therapy selection in hematological malignancies. Distinct cytogenetic aberrations leading to the formation of fusion genes are found in more than 40% of pediactric cases of acute myeloid leukemia (AML); however, the tumor cells in approximately 20% of these patients display cytogenetically normal karyotype (NK-AML). Here we present the analysis of the mutational profiles of leukemic cells collected from pediatric AML cases without known clinically significant chromosomal aberrations aimed at identifying AML specific markers. In 34 pediatric cases of different AML types, the coding regions of 26 genes involved in the AML pathogenesis were analyzed by massive parallel sequencing. Sequencing revealed the somatic mutations in genes that are involved in various intracellular signaling pathways, including the CEBPA, ETV, IDH1, JAK2, and NRAS genes. In addition, rare genetic variants were found in CUX1, FLT3, TET2, PTPN11, and NUP98 genes. This data may contribute to the understanding of the mechanisms of malignant cell transformation in the case of leukemogenesis.
About the authors
L. G. Ghukasyan
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: nased@biochip.ru
Russian Federation, Moscow, 119991
G. S. Krasnov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: nased@biochip.ru
Russian Federation, Moscow, 119991
O. V. Muravenko
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: nased@biochip.ru
Russian Federation, Moscow, 119991
L. V. Baidun
Russian Children’s Clinical Hospital, Pirogov Russian National Research Medical University
Email: nased@biochip.ru
Russian Federation, Moscow, 119571
S. Z. Ibragimova
Scientific Research Institute of Haematology and Blood Transfusion
Email: nased@biochip.ru
Uzbekistan, Tashkent, 100185
T. V. Nasedkina
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Dmitry Rogachev National Medical and Research Center of Pediatric Haematology,Oncology and Immunology
Author for correspondence.
Email: nased@biochip.ru
Russian Federation, Moscow, 119991; Moscow, 119117
Supplementary files
